BridgeBio Oncology Therap... (BBOT)
NASDAQ: BBOT
· Real-Time Price · USD
11.47
-0.23 (-1.97%)
At close: Sep 29, 2025, 3:59 PM
11.35
-1.05%
After-hours: Sep 29, 2025, 07:29 PM EDT
Company Description
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors.
Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways.
The company recently went public through a business combination with Helix Acquisition Corp.
II, raising approximately $450 million to advance clinical development.
The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
BridgeBio Oncology Therapeutics Inc.
| Country | United States |
| IPO Date | Aug 12, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Eli M. Wallace |
Contact Details
Address: 256 E. Grand Avenue No city data available, United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | BBOT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001869105 |
| CUSIP Number | n/a |
| ISIN Number | US1079241022 |
| Employer ID | 00-0000000 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Bihua Chen | Chairperson & Chief Executive Officer |
| Caleb Jonathan Tripp | Chief Financial Officer |
| Nebojsa Obradovic | Chief Legal Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 10, 2025 | 424B3 | Filing |
| Sep 03, 2025 | SCHEDULE 13G | Filing |
| Aug 29, 2025 | S-1 | Filing |
| Aug 28, 2025 | 4 | Filing |
| Aug 28, 2025 | 4 | Filing |
| Aug 28, 2025 | 4 | Filing |
| Aug 28, 2025 | 4 | Filing |
| Aug 28, 2025 | 4 | Filing |
| Aug 28, 2025 | 4 | Filing |
| Aug 28, 2025 | 4 | Filing |